As the treatment combining DRD1 antagonist SCH23390 and DRD2 agonist quinpirole is effective in ameliorating deficits associated with multiple behaviors in Trappc9-KO mice (19), we reasoned that this treatment might also be beneficial in controlling obesity or NAFLD in Trappc9-KO mice. This evidence concerns the gene DRD1 and metabolic dysfunction-associated steatotic liver disease.